| Website | pronota.com |
| Category | BioTech |
| Phone | +32 (0)9 241 11 64 |
| info@pronota.com | |
| Employees | |
| Founded | 10/04 |
| Description | Molecular Diagnostics |
| TOTAL | $32.7M |
| FUNDING TOTAL | $32.7M |
| Series A, 4/06 Life Sciences Partners Johnson & Johnson Development Corporation | $7.8M |
| Series A, 8/06 Gimv Life Sciences Partners KBC Private Equity Baekeland Funds | $10.6M |
| Grant, 10/06 | $2.2M |
| Grant, 7/07 | $2.8M |
| Series B, 6/09 Life Sciences Partners Gimv Biotech Fund Flanders KBC Private Equity Johnson & Johnson Development Corporation Baekeland Funds VIB | $7.36M |
| Series B, 10/09 MP Healthcare Venture Management | $1.95M |
Pronota NV develops and commercializes protein biomarker discovery platforms for the identification of candidates for drug development, and diagnostic products for diagnosis and personalized treatment of diseases. Its technologies include MASStermind, a protein biomarker discovery platform that enables the identification and relative quantitation of proteins; and MASSterclass, a mass spectrometry based antibody-free assay platform that provides contract assay development and biomarker screening services. The company also provides contract proteomic research and development services to the pharmaceutical and diagnostic industry. Pronota NV was formerly known as Peakadilly NV and changed its name to Pronota NV in November 2006. The company was founded in 2004 and is based in Zwijnaarde, Belgium.
